for people ages 18 years and up (full criteria)
at San Francisco, California
study started
completion around
Principal Investigator
by Jin Ge, MD, MBA



The aim of the study is to compare the effect of CirrhosisRx, a novel clinical decision support (CDS) system for inpatient cirrhosis care, versus "usual care" on adherence to national quality measures and clinical outcomes for hospitalized patients with cirrhosis.

Official Title

Pragmatic Randomized Controlled Trial to Evaluate the Effect of CirrhosisRx, a Novel Clinical Decision Support System, on Guideline-adherence and Clinical Outcomes for Patients With Cirrhosis


Each year, there over 200,000 hospitalizations for cirrhosis in the United States. Over one-third of these patients are readmitted within 30 days, and up to 10% will die in the hospital. Despite national quality measures and care guidelines, cirrhosis care remains suboptimal and highly variable.

Clinical Decision Support (CDS) systems present an attractive strategy to improve guideline-adherence due to low implementation costs. These systems, however, remain largely untested in cirrhosis care and it remains unknown whether they are effective at improving guideline-adherence and whether improving guideline-adherence changes clinical outcomes in cirrhosis care. The investigators have designed "CirrhosisRx," a cirrhosis-specific CDS system, to address these evidence gaps.

This study intends to compare effect of CirrhosisRx versus "usual care" on adherence to quality measures and clinical outcomes through a pragmatic randomized controlled trial (pRCT). Randomization will be based on stepped-wedge cluster randomization of treatment teams at our institution.


Cirrhosis, Decision Support Systems, Clinical, Liver Cirrhosis, Fibrosis, CirrhosisRx CDS, CirrhosisRx


You can join if…

Open to people ages 18 years and up

  • All adult (age ≥ 18 years) patients who have a previous history of cirrhosis identified based on 1+ chronic liver disease and 1+ cirrhosis (or its complications) International Classification of Diseases, Revision 10 diagnosis codes admitted at our institution.

You CAN'T join if...

  • Children (age < 18 years)
  • patients who do not meet the cirrhosis definition criteria as noted above
  • ambulatory patients


  • UCSF Medical Center
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Jin Ge, MD, MBA
    I am a gastroenterologist and transplant hepatologist who cares for patients with liver diseases, including patients waiting for a liver transplant. My research focuses on using clinical informatics, data science and artificial intelligence to improve care for patients with complex medical issues and advanced liver disease.


not yet accepting patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Expecting 2106 study participants
Last Updated